Thrombotische Mikroangiopathien

Zusammenfassung

Thrombotische Mikroangiopathien sind durch mikrovaskuläre Okklusion gekennzeichnet. Klinisch finden sich eine Thrombozytopenie und mikroangiopathische hämolytische Anämie. Zusätzliche Symptome der Organischämie können in variabler Konstellation ausgeprägt sein. Die thrombotischen Mikroangiopathien sind pathophysiologisch heterogen. Sie umfassen die thrombotisch-thrombozytopenische Purpura und das hämolytisch-urämische Syndrom. Daneben sind eine Assoziation mit verschiedenen Erkrankungen und Medikamenten und ein Auftreten nach allogener hämatopoetischer Stammzelltransplantation bekannt.

Summary

Thrombotic microangiopathies are disorders of microvascular occlusion and are characterized by thrombocytopenia and microangiopathic haemolytic anaemia. Varying additional signs and symptoms of organ ischaemia may be present. Thrombotic microangiopathies are pathophysiologically heterogenous disorders and include primarily thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Besides this, they may occur in association with certain diseases or drugs, or after allogeneic haematopoietic stem cell transplantation.

Schlüsselwörter

Thrombotische Mikroangiopathie - thrombotisch-thrombozytopenische Purpura - hämolytisch-urämisches Syndrom

Keywords

Thrombotic microangiopathy - thrombotic thrombocytopenic purpura - haemolytic uraemic syndrome

• Literatur

• 1 Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573.
• 2 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-159.
• 3 Antoine G, Zimmermann K, Plaimauer B. et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factorcleaving protease activity by recombinant human ADAMTS-13. Br J Haematol 2003; 120: 821-824.
• 4 Barbot J, Costa E, Guerra M. et al. Ten years of prophylactic treatment with fresh frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113: 649-651.
• 5 Bell WR, Braine HG, Ness PM. et al. Improved survival in thrombotic thrombocytopenic purpura- hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
• 6 Bennett CL, Davidson CJ, Raisch DW. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Int Med 1999; 159: 2524-2528.
• 7 Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K. et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Int Med 1998; 128: 541-544.
• 8 Besbas N, Karpman D, Landau D. et al. A classification of hemolytic uremic syndroms and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431.
• 9 Bianchi V, Robles R, Alberio L. et al. Von Willebrand factor-cleaving protease (ADAMTS-13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
• 10 Caprioli J, Noris M, Brioschi S. et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
• 11 Cleary TG. Cytotoxin-producing Escherichia coli and the hemolytic uremic syndrome. Pediatr Clin N Am 1988; 35: 485-501.
• 12 Dong JF, Moake JL, Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 13 Fontana S, Gerritsen HE, Kremer Hovinga J. et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor cleaving protease. Br J Haematol 2001; 113: 100-102.
• 14 Fontana S, Kremer Hovinga JA, Lämmle B. et al. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006; 90: 245-254.
• 15 Fontana S, Kremer Hovinga JA, Studt JD. et al. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 2004; 41: 48-49.
• 16 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Wille-brand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437-454.
• 17 Furlan M, Robles R, Galbusera M. et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
• 18 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
• 19 Furlan M, Robles R, Solenthaler M. et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
• 20 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factorcleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-2846.
• 21 Gasser C, Gautier E, Steck A. et al. Hämolytischeurämische Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
• 22 Griffin PM, Tauxe RV. The epidemiology of infections caused by Escherichia coli o157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991; 13: 60-98.
• 23 Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura und hemolytic uremic syndrome are distinct pathologic entities. Arch Pathol Lab Med 2003; 127: 834-839.
• 24 Karpac CA, Li X, Terrell DR. et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141: 696-707.
• 25 Klaus C, Plaimauer B, Studt JD. et al. Epitope mapping of ADAMTS-13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519.
• 26 Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007; 19: 148-154.
• 27 Kokame K, Matsumoto M, Fujimura Y, Myata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-612.
• 28 Kokame K, Nobe Y, Kokubo Y. et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
• 29 Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-1148.
• 30 Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F. et al. Splenectomy in relapsing and plasma- refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-324.
• 31 Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3: 1663-1675.
• 32 Lämmle B, Kremer Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008; 93: 172-177.
• 33 Langer F, Bergmann F, Budde U. et al. Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Br J Haematol 2002; 118: 271-274.
• 34 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 35 Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease activity is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol 2001; 112: 1087-1088.
• 36 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
• 37 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
• 38 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
• 39 Moore JC, Hayward CP, Warkentin TE, Kelton JG. Willebrand factor protease activity associated with thrombocytopenic disorders. Bloood 2001; 98: 1842-1846.
• 40 Mori Y, Wada H, Gabazza EC. et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580.
• 41 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924; 24: 21-24.
• 42 Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child 1997; 76: 518-521.
• 43 Padilla A, Moake JL, Bernardo A. et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103: 2150-2156.
• 44 Peyvandi F, Lavoretano S, Palla R. et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
• 45 Plaimauer B, Zimmermann K, Völkel D. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS-13). Blood 2002; 100: 3626-3632.
• 46 Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving proteaseprotease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101: 948-948.
• 47 Rock GA, Shumak KH, Buskard NA. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
• 48 Rüfer A, Brodmann D, Gregor M. et al. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. Swiss Med Wkly 2007; 137: 518-524.
• 49 Ruutu T, Barosi G, Benjamin RJ. et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group. Haematologica 2007; 92: 95-100.
• 50 Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Int Med 1995; 122: 569-572.
• 51 Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo) 2001; 130: 475-480.
• 52 Studt JD, Böhm M, Budde U. et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-1887.
• 53 Studt JD, Kremer Hovinga JA, Antoine G. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS-13 inhibitor: in vitro inhibition of ADAMTS-13 activity by hemoglobin. Blood 2005; 105: 542-544.
• 54 Studt JD, Kremer Hovinga JA, Radonic R. et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS-13 inhibitory autoantibodies in identical twins. Blood 2004; 103: 4195-4197.
• 55 Taylor CM. Complement factor H and the haemolytic uraemic syndrome. Lancet 2001; 358: 1200-1202.
• 56 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086.
• 57 Tripodi A, Chantarangkul V, Böhm M. et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609.
• 58 Tripodi A, Peyvandi F, Chantarangkul V. et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-1541.
• 59 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
• 60 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
• 61 Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-2179.
• 62 Uemura M, Fujimura Y, Matsumoto M. et al. Comprehensive analysis of ADAMTS 13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
• 63 Van der Plas RM, Schiphorst ME, Huizinga EG. et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantationassociated thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-3802.
• 64 Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol 2004; 41: 41-47.
• 65 Veyradier A, Obert B, Houllier A. et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1772.
• 66 Vesely SK, George JN, Lämmle B. et al. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
• 67 Yomtovian R, Niklinski W, Silver B. et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-795.
• 68 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
• 69 Zheng X, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS-13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 404-4049.
• 70 Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol Mech Dis 2008; 3: 249-277.